CellOrigin Closed a New Round of Investment to Jump-start its iPSC Immune Cell Therapy Products Toward Clinics
/PRNewswire/ -- On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of...
United States Jin Zhang Scripps Research Institute Research Scientist Head Of Cell Therapy Department Boston Children Hospital Harvard Medical School
Source: prnewswire.com